Valganciclovir as treatment for cytomegalovirus disease in solid organ transplant recipients

Clinical Infectious Diseases

Volumn 46, Issue 1, 2008, Pages 20-27

  Len Abad, Oscar ^a,b   Gavaldà, Joan ^a   Aguado, José María ^a   Borrell, Núria ^a   Cervera, Carlos ^a   Cisneros, José Miguel ^a   Cuervas Mons, Valentín ^a   Gurguí, Mercè ^a   Martin Dávila, Pilar ^a   Montejo, Miguel ^a   Muñoz, Patricia ^a   Bou, Germán ^a   Carratalà, Jordi ^a   Torre Cisneros, Julián ^a   Pahissa, Albert ^a  

^a Spanish Network for Research on Infection in Transplantation ^*  (Spain)

^b NONE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CIDOFOVIR; FOSCARNET; GANCICLOVIR; VALGANCICLOVIR;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DATA BASE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; FEMALE; GRAFT RECIPIENT; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELAPSE; TREATMENT DURATION; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ANTIVIRAL AGENTS; COHORT STUDIES; CYTOMEGALOVIRUS INFECTIONS; DRUG THERAPY, COMBINATION; FEMALE; GANCICLOVIR; HUMANS; IMMUNOCOMPROMISED HOST; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; TRANSPLANTATION; TRANSPLANTATION IMMUNOLOGY;

EID: 39349116597     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/523590     Document Type: Article

References (23)

1. Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med 1998; 338:1741-51.
2. Ljungman P. β-Herpesvirus challenges in the transplant recipient. J Infect Dis 2002; 186(Suppl 1):S99-109.
3. Singh N. Preemptive therapy versus universal prophylaxis with ganciclovir for cytomegalovirus in solid organ transplant recipients. Clin Infect Dis 2001; 32:742-51.
4. Limaye AP, Corey L, Koelle DM, et al. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid organ transplants. Lancet 2000; 356:645-9.
5. Paya CV, Wilson JA, Espy MJ, et al. Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial. J Infect Dis 2002; 185:854-60.
6. Gane E, Saliba F, Valdecasas G, et al. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients: results of multicenter, multinational clinical trial. Lancet 1997; 350:1729-33.
7. Pescovitz MD, Rabkin J, Merion RM, et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother 2000; 44:2811-5.
8. Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4:611-20.
9. Martin DF, Sierra-Madero J, Walmsley S, et al. Valganciclovir study group: a controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N Engl J Med 2002; 346:1119-26.
10. Babel N, Gabdrakhmanova L, Juergensen JS, et al. Treatment of cytomegalovirus disease with valganciclovir in renal transplant recipients: a single center experience. Transplantation 2004; 78:283-5.
11. Devyatko E, Zuckermann A, Ruzicka M, et al. Pre-emptive treatment with oral valganciclovir in management of CMV infection after cardiac transplantation. J Heart Lung Transplant 2004; 23:1277-82.
12. Fellay J, Venetz JP, Aubert JD, Seydoux C, Pascual M, Meylan PRA. Treatment of cytomegalovirus infection or disease in solid organ transplant recipients with valganciclovir. Transplant Proc 2005; 37:949-51.
13. Kalpoe JS, Schippers EF, Eling Y, Sijpkens YW, de Fijter JW, Kroes ACM. Similar reduction of cytomegalovirus DNA load by oral valganciclovir and intravenous ganciclovir on pre-emptive therapy after renal and renal-pancreas transplantation. Antivir Ther 2005; 10:119-23.
14. Singh N, Wannstedt C, Keyes L, Gayowski T, Wagener MM, Cacciarelli TV. Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset cytomegalovirus disease. Transplantation 2005; 79:85-90.
15. Zamora MR, Nicolls MR, Hodges TN, et al. Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of CMV infection following lung transplantation. Am J Transplant 2004; 4:1635-42.
16. Mattes FM, Hainsworth EG, Hassan-Walker AF, et al. Kinetics of cytomegalovirus load decrease in solid-organ transplant recipients after preemptive therapy with valganciclovir. J Infect Dis 2005; 191:89-92.
17. Diaz-Pedroche C, Lumbreras C, San Juan R, et al. Valganciclovir pre-emptive therapy for the prevention of cytomegalovirus disease in high-risk seropositive solid-organ transplant recipients. Transplantation 2006; 82:30-5.
18. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34:1094-7.
19. Gerna G, Revello MG, Percivalle E, Morina F. Comparison of different immunostaining techniques and monoclonal antibodies to the lower matrix phosphoprotein (pp65) for optimal quantitation of human cytomegalovirus antigenemia. J Clin Microbiol 1992; 30:1232-7.
20. Torre-Cisneros J, Fortun J, Aguado JM, et al. Consensus document from GESITRA-SEIMC on the prevention and treatment of cytomegalovirus infection in transplanted patients [in Spanish]. Enferm Infecc Microbiol Clin 2005; 23:424-37.
21. Boivin G, Goyette N, Gilbert C, et al. Absence of cytomegalovirus- resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients. J Infect Dis 2004; 189:1615-8.
22. Fisher RA, Saggi BH, Ferreira-Gonzalez A, Wolfe L, Posner MP. Prospective validation of quantitative PCR for management of CMV disease in solid-organ transplant patients. Transplantation 2002; 74:573-6.
23. Preiksaitis JK, Brennan DC, Fishman J, Allen U. Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. Am J Transplant 2005; 5:218-27.